PDS Biotech hosts virtual KOL event on PDS0301 in advanced colorectal cancer with liver metastases

Bitget2026/10/06 12:07

PDS Biotech will host a virtual KOL event on Oct. 15, 2026 at 8:00 a.m. ET. Discussion will center on Phase 2 clinical outcomes for PDS0301 in advanced liver-associated cancers, highlighting metastatic colorectal cancer. Program will cover second- and third-line unresectable MSS or pMMR colorectal liver metastases, a setting where immunotherapy has largely underperformed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9840213) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.